31 terminated. 31 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Terminated 31 |
| Phase 1 | 6 | Terminated 6 |
| Phase 3 | 1 | Terminated 1 |
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Epcoritamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Genmab | 111 | 2023-03-06 | 2026-10-23 |
| Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma Polatuzumab vedotin (PV), Rituximab, Hyaluronidase - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 5 | 2023-02-17 | 2026-04-16 |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine, Rituximab - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 41 | 2022-06-21 | 2025-01-30 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] THOR-707, Pembrolizumab - Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Sanofi | 14 | 2021-12-07 | 2025-12-24 |
| Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS Glucarpidase 1000 UNT [Voraxaze] - Diffuse Large B-Cell Lymphoma, Drug Toxicity | Phase 2 | Terminated | Fundacion CRIS de Investigación para Vencer el Cáncer | 3 | 2021-07-19 | 2024-05-13 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Deepa Jagadeesh | 13 | 2021-04-28 | 2025-02-07 |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma Copanlisib - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 37 | 2020-08-18 | 2025-08-08 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Loncastuximab Tesirine, Ibrutinib - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | ADC Therapeutics S.A. | 136 | 2018-12-01 | 2024-02-06 |
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) TAK-659 - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Calithera Biosciences, Inc | 49 | 2017-10-10 | 2023-02-08 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Thymoglobulin, Bortezomib, Tacrolimus - Acute Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Emory University | 5 | 2016-09-01 | 2018-04-30 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma Metformin - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Rush University Medical Center | 2 | 2016-02-01 | 2017-11-17 |
| Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Chicago | 2 | 2015-11-01 | 2018-06-06 |
| Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Metformin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Rush University Medical Center | 5 | 2015-07-01 | 2022-09-28 |
| A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL DPX-Survivac, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 4 | 2015-01-01 | 2021-06-22 |
Showing 20 of 31. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (31) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Mantle-Cell (7) · Lymphoma (6) · Recurrence (6) · Lymphoma, Follicular (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Myelodysplastic Syndromes (2) · Waldenstrom Macroglobulinemia (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Drug-Related Side Effects and Adverse Reactions (1) · Graft vs Host Disease (1)
Hemic and Lymphatic Diseases (31) · Immune System Diseases (31) · Immunoproliferative Disorders (31) · Lymphatic Diseases (31) · Lymphoma, B-Cell (31) · Lymphoproliferative Disorders (31) · Neoplasms (31) · Neoplasms by Histologic Type (31) · Lymphoma, Non-Hodgkin (28) · Lymphoma (25) · Disease Attributes (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Chronic Disease (7) · Leukemia, B-Cell (7)
Rituximab (8) · Cyclophosphamide (5) · Lenalidomide (5) · Dexamethasone (3) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (2) · Bendamustine Hydrochloride (2) · Doxorubicin (2) · Metformin (2) · Prednisone (2) · Vincristine (2) · ibritumomab tiuxetan (2) · loncastuximab tesirine (2) · obinutuzumab (2) · Antilymphocyte Serum (1) · Bortezomib (1)
ADC Therapeutics S.A. (2) · Genmab (2) · Gilead Sciences (2) · Pfizer (2) · Rush University Medical Center (2) · Anne Beaven, MD (1) · Antengene Corporation (1) · Calithera Biosciences, Inc (1) · Celgene Corporation (1) · Chulalongkorn University (1) · Deepa Jagadeesh (1) · Emory University (1) · Fondazione Italiana Linfomi - ETS (1) · Fred Hutchinson Cancer Center (1) · Fudan University (1)
United States (20) · Italy (8) · Spain (8) · Canada (4) · France (4) · United Kingdom (4) · Belgium (3) · Japan (3) · South Korea (3) · Australia (2) · China (2) · Israel (2) · Poland (2) · Argentina (1) · Austria (1)
Reem Karmali, MD (2) · Adolfo De la Fuente, PD (1) · Andrew Spencer, MD (1) · Anne W. Beaven, MD (1) · Barbara Botto, MD (1) · Christopher Dittus, DO, MPH (1) · Deepa Jagadeesh, MD, MPH (1) · Ken Cohen (1) · Masumi Ueda Oshima (1) · Owen A O'Connor, MD, PhD (1)
PMID 25696919, PMID 26968534, PMID 33683917, PMID 41043099, PMID 42285113
2009 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1), P01CA078902 (1), P30CA014599 (1), P30CA015704 (1)